Intravenous Immunoglobulin Market Analysis 2026

Global Intravenous Immunoglobulin Market Analysis from 2022 to 2034 Containing Market Size, Share along with its CAGR, Forecast and Trends

Intravenous Immunoglobulin Market Report Description

We have various report editions of Intravenous Immunoglobulin Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Impact of Tariff Trumph on Pharmaceuticals Industry

The April 2025 “Liberation Day Tariffs” (10–46%) have disrupted global pharmaceutical trade, raising costs for APIs, packaging, and machinery from China and India. Generic drug makers, biopharma, vaccines, and CMOs face higher expenses, supply chain delays, and regulatory hurdles, while EU retaliation has further strained U.S. exports. Clinical trials are also delayed due to tariffs on drugs and kits. In this landscape, market research is vital, providing real-time data on pricing, suppliers, and tariff impacts to help companies optimize supply chains, find alternative hubs, and maintain competitiveness.

Competitive Landscape: Intravenous Immunoglobulin Market

In order to meet the increasing demands of consumers the industry players are now investing and giving more attention to their research and development of Intravenous Immunoglobulin so that they sustain and survive in the competition. ensuring a competitive edge. Robust distribution networks and adherence to quality standards amplify market presence, fostering an environment where agility and innovation define industry leaders.

Recent Development 

In July 2023, GC Biopharma announced that the U.S. Food and Drug Administration (FDA) had completed its preliminary review for the marketing authorization of its blood product, Alyglo (GC5107B, 10% intravenous immunoglobulin). The FDA has also initiated the review process for the final approval of GC5107B, as stated by the company. GC Biopharma submitted a Biologics License Application (BLA) for Alyglo on July 14, and the FDA conducted a preliminary assessment two weeks later, on August 4. Following the receipt of the BLA, the FDA will carry out a preliminary evaluation for a period of 60 days, after which it will begin the comprehensive review process if the data provided is deemed adequate.
https://www.koreabiomed.com/news/articleView.html?idxno=21729 
In November 2023, Grifols, S.A. obtained approval from the FDA for its new immunoglobulin (Ig) purification and filling facility located in Clayton, North Carolina. This approval specifically pertains to Gamunex-C (immunoglobulin G brand), allowing the company to produce an additional 16 million grams of the therapy each year, thereby increasing its total global production capacity to 60 million grams.
https://www.grifols.com/en/view-news/-/news/grifols-receives-fda-approval-for-expanded-immunoglobulin-purification-and-filling-capacity-at-its-north-carolina-site 
In April 2023, Baxter AG introduced a new liquid IVIG product, KIOVIG, which was developed using a modified Cohn fractionation process and ion exchange chromatography.
https://emedicine.medscape.com/article/210367-overview#:~:text=Baxter%20AG%20created%20a%20new,with%20IgA%20deficiency%20is%20unclear. 
In March 2022, Sanofi and Seagen Inc. entered into an exclusive partnership to create, develop, and market antibody-drug conjugates (ADCs) aimed at three cancer targets. This collaboration will leverage Sanofi's proprietary monoclonal antibody (mAb) technology alongside Seagen's exclusive ADC technology.
https://www.sanofi.com/en/media-room/press-releases/2022/2022-03-16-10-18-19-2404147

Top Companies Market Share in Intravenous Immunoglobulin Industry: (In no particular order of Rank)

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive)

Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Which Region will dominate the Market in 2025, and Which Region is Expanding at the Fastest CAGR?

According to Cognitive Research, North America region dominated the market and accounted for the highest revenue of XX% in 2024 and it is projected that it will grow at a CAGR of XX% in the future. North America leads the world in intravenous immunoglobulin (IVIG) market, with a major share coming from the United States due to factors such as a well-developed healthcare system, high usage of IVIG, and a robust pharmaceutical sector. 
The United States is likely to have a dominant share of the market in North America. The main drivers fueling the expansion of the country's market are an established and properly organized health system; enhanced concentration on R&D; and powerful representation on the market of competitors. Also, increasing the incidence of target diseases like primary immunodeficiency diseases in the region will further drive the growth of the market. 
For instance, in 2023, the National Institute of Allergy and Infectious Diseases (NIAID) (.gov) stated more than 200 types of Primary Immune Deficiencies (PIDs) were diagnosed in the United States, occurring in nearly 500,000 individuals. 
https://www.niaid.nih.gov/diseases-conditions/primary-immune-deficiency-diseases-pidds 

Asia Pacific has been growing at a CAGR of XX% during the forecast period. Asia-Pacific region is inhabited by a large percentage of the world's population, including highly populated nations such as China and India. With a high population base, people are likely to need IVIG treatment, leading to high market growth. The Asia-Pacific has experienced high growth in its pharmaceutical sector, with numerous local and foreign companies actively involved in manufacturing and distributing IVIG products. A competitive market boosts innovation, lowers prices, and increases product supply, all of which will spur growth in the IVIG market. Government support is on the rise, as well as the growth of research and development activities, with an increasing amount of healthcare reforms to propel the intravenous immunoglobulin market. The Asia-Pacific region is showing a gradual increase in the IVIG market due to rising health expenditure, population aging, and lifestyle changes. 
A study from New South Wales, Australia showed the use of IVIg is increasing with 12.0% in annual percentage per year, reflecting 97.7% throughout the study. 
https://onlinelibrary.wiley.com/doi/10.1111/imj.16175#:~:text=Results.%20During%20the%20study%20period%2C%20169%20453,97.7%%20increase%20(91.6%E2%80%93104%)%20over%20the%20study%20period. 
 

The current report Scope analyzes Intravenous Immunoglobulin Market on 6 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Switzerland, Luxembourg, Rest of Europe)
• Asia Pacific (China, Japan, South Korea, India, Australia, Singapore, Taiwan, South East Asia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East (Saudi Arabia, Turkey, UAE, Egypt, Qatar, Rest of Middle East)
• Africa (East Africa, West Africa, North Africa, South Africa)

The above graph is for illustrative purposes only.

Author's Conclusion

Author's Detail

Supriya Yadav

Research Analyst

LinkedIn | Profile | Book Appointment

Supriya Yadav is a dedicated market research professional with expertise in the aerospace and defence industry. At Cognitive Market Research, she focuses on delivering strategic insights into aviation advancements, defence technologies, and global security trends shaping the future of the sector.

Her research covers areas such as military modernization, commercial aviation growth, space exploration, and defence procurement strategies. With a strong analytical mindset and attention to technological evolution, Supriya provides data-driven intelligence that supports innovation, strategic planning, and informed decision-making within the aerospace and defence domain.